- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03835442
A Placebo Controlled Trial With Baclofen for the Treatment of GERD Patients With Incomplete PPI Response
Reflux (acid and non-acid) mainly occurs during transient LES relaxations (TLESRs). The gamma-aminobutyric acid (GABA) receptor type B agonist baclofen was shown to inhibit TLESRs, thereby significantly decreasing acid reflux after a meal in healthy controls and in patients with GERD.
The primary objective of this study is to assess the efficacy (assessed by reflux symptom questionnaire and pH-impedance recordings) of baclofen 10mg three times daily vs. placebo in GERD patients with an incomplete response to PPI therapy.
The secondary objective is to assess the predictive value of reflux assessment (by pH-impedance recordings) on the primary outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, parallel, double-blind, placebo-controlled, out-patient, single-center study. Eligible subjects will be randomly assigned to receive either oral baclofen 10 mg or placebo t.i.d for a period 4 weeks. After 4 weeks all patients will be given the standard dose of baclofen 10 mg t.i.d. (open label), for another 4 weeks. The b.i.d. PPI therapy will be continued for the entire study duration.
Approximately 90 evaluable subjects with typical GERD symptoms (heartburn and/or regurgitation) will participate in this study and will be randomized on a 1:1 basis: 45 subjects each will be in the placebo and baclofen 10 mg three times daily group. Subjects will be considered to have completed the study if they complete the week 4 visit.
Medication will consist of identically-looking capsules of baclofen or placebo. Patients will take 1 capsule containing 5 mg baclofen with meals t.i.d for 7 days and then 1 capsule containing 10 mg baclofen with meals t.i.d for the remaining 21 days.
Prior to visit 1, all subjects included in the study will undergo a 24 hr pH-impedance study which was requested by the treating physician. This investigation is part of the standard clinical work up and will not be part of the study protocol.
Informed consent is to be signed and dated by the subject before any study related procedures are performed. The date of each visit to the clinic and the date and time of the last dose of test article will be recorded.
Throughout the study patients will be asked to complete daily a short questionnaire (ReQuest) for reflux symptoms.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 - 75 years old
- History of typical (heartburn/regurgitation) or atypical GERD symptoms during PPI treatment, at least 3 times per week for 12 weeks. Daily intake of PPI treatment 12 weeks prior to inclusion.
- Sexually active women of child bearing potential participating in the study must use a medically acceptable form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception.
- Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.
Exclusion Criteria:
- Endoscopic signs of severe erosive esophagitis (≥ grade C, Los Angeles classification) on endoscopy performed during PPI treatment in the 6 months prior to screening.
- Systemic diseases, known to affect esophageal motility.
- Surgery in thorax or in the upper part of the abdomen.
- Treatment with baclofen prior to the start of the study.
- Regular use of medications such as: anticholinergics, tricycle antidepressants.
- Significant neurological, respiratory, hepatic, renal, haematological, cardiovascular, metabolic or gastroinestinal cerebrovascular disease as judged by the investigator
- Absence of PPI intake for at least 2 consecutive days in the 2 weeks prior to the screening.
- Pregnancy or breast feeding.
- History of poor compliance. History of/or current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent. (well-compensated depression is allowed).
- History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: baclofen arm
baclofen 10mg tid for 4 weeks
|
baclofen 10mg tid for 4 weeks
Other Names:
|
Placebo Comparator: placebos arm
placebo tid for 4 weeks
|
placebo tid for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy of baclofen on reflux symptom questionnaire
Time Frame: Change from baseline in ReQuest scores at 4 weeks
|
To assess the effect of baclofen on reflux symptom questionnaire by ReQuest
|
Change from baseline in ReQuest scores at 4 weeks
|
efficacy of baclofen on pH-impedance recordings
Time Frame: Change from baseline in reflux parameters (total number of reflux episodes) on 24h pH-impedance monitoring at 4 weeks
|
To assess of baclofen on 24 hour pH-impedance recordings
|
Change from baseline in reflux parameters (total number of reflux episodes) on 24h pH-impedance monitoring at 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive value of the reflux monitoring
Time Frame: Is SAP at baseline predictor of response at 4 weeks
|
To assess the predictive value of the 24 hour pH-impedance monitoring (symptom association probability = SAP) on the primary outcome
|
Is SAP at baseline predictor of response at 4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jan Tack, PhD, MD, UZ Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Gastroesophageal Reflux
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- GABA Agents
- Neuromuscular Agents
- Muscle Relaxants, Central
- GABA Agonists
- GABA-B Receptor Agonists
- Baclofen
Other Study ID Numbers
- S51996
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastro Esophageal Reflux
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
-
Asian Institute of Gastroenterology, IndiaCompletedGastro Esophageal Reflux DiseaseIndia
-
Medtronic - MITGCompletedGastro Esophageal Reflux DiseaseIsrael
-
Vrije Universiteit BrusselCompletedGastro-esophageal RefluxBelgium
-
Mayo ClinicWithdrawnGastro-esophageal Reflux Disease (GERD)United States
-
Medtronic - MITGWithdrawnGastro Esophageal Reflux DiseaseIsrael
-
MAAB (Shanghai) Medical Device LimitedRD Biomed LtdCompletedGastro-esophageal Reflux DiseaseChina
-
Vrije Universiteit BrusselCompleted
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedGastro-esophageal Reflux Disease (GERD)China
-
James J. Peters Veterans Affairs Medical CenterUnknownGastro Esophageal Reflux DisorderUnited States
Clinical Trials on Baclofen
-
Tanta UniversityUnknownLiver Cirrhosis | Muscle CrampsEgypt
-
Impax Laboratories, LLCCompletedMultiple SclerosisUnited States, Canada, Estonia, Latvia, Ukraine
-
University of MinnesotaParalyzed Veterans of America Research FoundationCompleted
-
Amsterdam UMC, location VUmcMedtronicNot yet recruitingCerebral Palsy | Intrathecal Baclofen
-
Allaysis, LLCUniversity of MinnesotaUnknownIntravenous Baclofen
-
Hospices Civils de LyonNot yet recruitingBenzodiazepine DependenceFrance
-
Tanta UniversityRecruitingMorbid Obesity | Postoperative Nausea and Vomiting | Laparoscopic Sleeve GastrectomyEgypt
-
Vanderbilt UniversityMedtronicCompleted
-
Shaare Zedek Medical CenterTerminatedCerebral PalsyIsrael
-
Imperial College LondonMedical Research CouncilCompleted